With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.859518-35-7,tert-Butyl 3-cyanopiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.,859518-35-7
To a solution of tert-butyl 3-cyanopiperazine-1-carboxylate (21.1 g, 0.1 mol) and aqueous formaldehyde (24 g, 37% in water) in THF was added sodium cyanoborohydride (31.5 g, 0.5 mol) in small portions. The reaction mixture was aged at ambient temperature overnight then diluted with water and extracted with ethyl acetate. The organic phase was washed with saturated aqueous sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude product was purified by column chromatography to provide the title compound. 1H NMR (400 MHz, MeOD) delta 4.23-4.18 (m, 1H), 4.01-3.97 (br, 1H), 3.92-3.90 (br, 1H), 2.92-2.89 (br, 1H), 2.88-2.87 (br, 1H), 2.65-2.62 (m, 1H), 2.378 (s, 3H), 2.36-2.33 (m, 1H), 1.47 (s, 9H).
As the paragraph descriping shows that 859518-35-7 is playing an increasingly important role.
Reference£º
Patent; JANSSEN PHARMACEUTICA NV; ORTHO-CLINICAL DIAGNOSTICS, INC; DONAHUE, Matthew Garrett; GONG, Yong; SALTER, Rhys; HRYHORENKO, Eric; DECORY, Thomas R.; REMMERIE, Bart M.; SANKARAN, Banumathi; WO2014/31587; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics